Hemangioma pathophysiology: Difference between revisions
Sergekorjian (talk | contribs) |
Sergekorjian (talk | contribs) No edit summary |
||
Line 35: | Line 35: | ||
:*Involution phase | :*Involution phase | ||
===Proliferation phase=== | =====Proliferation phase===== | ||
*In most hemangiomas, eighty percent of proliferation occurs by three months of life but may last longer.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | *In most hemangiomas, eighty percent of proliferation occurs by three months of life but may last longer.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*During proliferation, rapid growth can lead to exhaustion of blood supply with resulting ischemia, necrosis, ulceration, and bleeding. | *During proliferation, rapid growth can lead to exhaustion of blood supply with resulting ischemia, necrosis, ulceration, and bleeding. | ||
===Quiescence phase=== | =====Quiescence phase===== | ||
*Following proliferation, hemangiomas enter a slower or no growth phase, known as quiescence.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | *Following proliferation, hemangiomas enter a slower or no growth phase, known as quiescence.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*This phase typically lasts from nine to twelve months of age. | *This phase typically lasts from nine to twelve months of age. | ||
===Involution phase=== | =====Involution phase===== | ||
*The final and unique phase of the hemangioma lifecycle is involution.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | *The final and unique phase of the hemangioma lifecycle is involution.<ref name="RichterFriedman2012">{{cite journal|last1=Richter|first1=Gresham T.|last2=Friedman|first2=Adva B.|title=Hemangiomas and Vascular Malformations: Current Theory and Management|journal=International Journal of Pediatrics|volume=2012|year=2012|pages=1–10|issn=1687-9740|doi=10.1155/2012/645678}}</ref> | ||
*This phase is marked by graying of the overlying skin and shrinking of the deeper components. | *This phase is marked by graying of the overlying skin and shrinking of the deeper components. |
Revision as of 22:12, 20 November 2015
Hemangioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hemangioma pathophysiology On the Web |
American Roentgen Ray Society Images of Hemangioma pathophysiology |
Risk calculators and risk factors for Hemangioma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Development of hemangioma is the result of genetic mutations, overexpression of angiogenic fators and downregulation of inhibitors of angiogenesis.[1] Hemangioma may be associated with POEMS syndrome and Castleman disease. On gross pathology, spongy with vascular compartments of various sizes separated by fibrous tissue are findings of hemangioma.[1] On microscopic histopathological analysis, channels lined by benign endothelium containing red blood cells are findings of hemangioma.[2]
Pathophysiology
The pathogenesis of hemangiomas has not been elucidated, but there are two competing theories.
First theory
- The first theory supports the notion that there is overexpression of angiogenic factors such as:[1]
- And there is downregulation of some inhibitors of angiogenesis such as:[1]
Second theory
- The second theory is that the presence of liver hemangiomas involves a genetic background of mutations.[1]
- Genetic errors in growth factor receptors have also been shown to affect development of hemangiomas.
- Metalloproteinases can accumulate in the endoplasmic reticulum of the tumor cells causing:
- Self-digestion
- Vacuole formation
- Cavernous hemangioma cell can downregulate Derlin-1.
- Derlin-1 is a protein that when overexpressed induces the dilated endoplasmic reticulum to return to its normal size.
Third theory
- The third theory suggests that hemangioma endothelial cells arise from disrupted placental tissue imbedded in fetal soft tissues during gestation or birth.[3]
- Markers of hemangiomas have been shown to coincide with those found in placental tissue.
- This is further supported by the fact that they are found more commonly in infants following:[3]
Growth Pattern
- Hemangiomas follow a predictable course with three distinct developmental phases:[3]
- Proliferation phase
- Quiescence phase
- Involution phase
Proliferation phase
- In most hemangiomas, eighty percent of proliferation occurs by three months of life but may last longer.[3]
- During proliferation, rapid growth can lead to exhaustion of blood supply with resulting ischemia, necrosis, ulceration, and bleeding.
Quiescence phase
- Following proliferation, hemangiomas enter a slower or no growth phase, known as quiescence.[3]
- This phase typically lasts from nine to twelve months of age.
Involution phase
- The final and unique phase of the hemangioma lifecycle is involution.[3]
- This phase is marked by graying of the overlying skin and shrinking of the deeper components.
- At the final stages of involution, a fibrofatty protuberance may remain.
Associated Conditions
Hemangioma may be associated with:
Gross Pathology
- Grossly hemangiomas are described as “spongy” with vascular compartments of various sizes separated by fibrous tissue.[1]
- Thrombi may be present and are well separated from the normal liver parenchyma despite the absence of a fibrous capsule.
Microscopic Pathology
On microscopic histopathological analysis channels lined by benign endothelium containing red blood cells are findings of hemangioma.[2]
Gallery
-
Intermediate magnification micrograph of a capillary hemangioma. H&E stain.[2]
-
Very high magnification micrograph of a capillary hemangioma. H&E stain.[2]
-
Histopathological image representing a cavernous hemangioma of the liver. Surgical excision of the lesion for the impending risk for rupture. H&E stain.[2]
-
Histopathological image reprsenting a cavernous hemangioma of the liver. H&E stain.[2]
Immunohistochemistry
Hemangioma is demonstrated by positivity to:[2]
- CD31 positive
- D2-40 negative
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Papafragkakis, Haris; Moehlen, Martin; Garcia-Buitrago, Monica T.; Madrazo, Beatrice; Island, Eddie; Martin, Paul (2011). "A Case of a Ruptured Sclerosing Liver Hemangioma". International Journal of Hepatology. 2011: 1–5. doi:10.4061/2011/942360. ISSN 2090-3456.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Microscopic features of hemangioma. Librepathology (2015). http://librepathology.org/wiki/index.php/Hemangioma. Accessed on November 12, 2015
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Richter, Gresham T.; Friedman, Adva B. (2012). "Hemangiomas and Vascular Malformations: Current Theory and Management". International Journal of Pediatrics. 2012: 1–10. doi:10.1155/2012/645678. ISSN 1687-9740.